Briumvi

(Ublituximab-xiiy)

Briumvi

Drug updated on 11/15/2023

Dosage FormInjection (intravenous; 150 mg/6 mL single-dose vials)
Drug ClassCD20-directed cytolytic antibodies
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • For the treatment of relapsing forms of multiple sclerosis (MS) in adults, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.